Motivation

Endomyocardial biopsy (EMB) screening is the standard-of-care for assessing allograft rejections (Figure 1a).

- Manual interpretation of EMBs is affected by substantial inter-rater variability, leading to mistreatment with immunosuppressive drugs, unnecessary follow-up biopsies, and worsened transplant outcomes.
- Objective and automated EMBs assessment could help mitigate these challenges.

Objective and Automated EMBs Assessment

- CRANE demonstrates potential of AI-integration into diagnostic workflow to:
  - Screen out negative cases
  - Reduce inter-rater variability
  - Increase efficiency of EMBs reads